CARLSBAD, Calif. (PRWEB) May 20, 2020
Luminec Pharmaceuticals, Inc. announced that it will submit a market research package to BARDA (Biomedical Advanced Research and Development Authority) in response to the currently-open broad agency announcement soliciting proposals for the development of COVID-19 disease countermeasures.
The submission will include technical information outlining the benefits and mechanism of action of the CRO-50 and X-2 products. It will also include multiple clinical case documents, including diagnosis, treatment and outcomes of patients treated with these products in previous severe acute respiratory syndrome coronavirus outbreaks (SARS-CoV-2). These products are based on ground-breaking research started by Professor Heberto Alcázar-Montenegro, co-founder of the Albert Szent-Györgyi Gerontological Center and the Hans Selye Institute of Scientific Research, and continued by his daughter, Dr. Susana Alcázar-Leyva, who currently serves as president of both institutions. Dr. Alcázar-Leyva is also a co-founder and director since 1986 of the Albert Szent-Györgyi Gerontology Center and serves Luminec Pharmaceuticals as its Executive Advisor and Board Director.
“We are pleased to offer our technology, historical clinical data and products for consideration in mitigating this current health issue” said Dr. Stephen Holt, Professor Emeritus and Co-Founder and Director of Scientific Development, Luminec Pharmaceuticals.
About Luminec Pharmaceuticals
Headquartered in Carlsbad, CA, Luminec Pharmaceuticals currently offers a unique array of all-natural OTC products and clinical services for both human and animal use. Luminec’s products include natural proprietary formulations based on the Schutt Paradigm of Free Amino Ion Alignment & Molecular Stability, in combination with proprietary partner technologies and nanoparticle delivery systems.
Luminec Pharmaceuticals is a wholly-owned subsidiary of Luminec Holding Corporation, a private holding company.